Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Clinical Trials
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Fact Sheet
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Fact Sheet
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Dec 8, 2020

Syros Closes $90.5 Million Strategic Financing

Dec 5, 2020

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Dec 5, 2020

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

Nov 16, 2020

Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 5, 2020

Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Nov 4, 2020

Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting

Oct 29, 2020

Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Oct 24, 2020

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Oct 9, 2020

Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting

Sep 10, 2020

Syros Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

RSS
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...29
    © 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Sitemap
    twitter logo linkedin logo